PepGen Inc.重申指导计划:2026年一季度公布Freedom-2试验5毫克/公斤队列数据,下半年公布10毫克/公斤队列数据

美股速递
Mar 05

生物技术公司PepGen Inc.近日再次确认其临床开发时间表,明确表示将于2026年第一季度发布Freedom-2临床试验中5毫克/公斤剂量组的研究数据。这一时间节点的重申为关注神经肌肉疾病治疗领域的投资者提供了明确预期。

此外,针对更高剂量的10毫克/公斤队列,公司计划在2026年下半年公布相关临床结果。两个关键数据集的陆续披露,将逐步揭示其候选疗法在杜氏肌营养不良症患者中的安全性与有效性表现。

此次指引的维持,反映了公司对临床开发进程的严格控制力,也为市场评估PepGen Inc.的技术平台价值和药物开发潜力提供了重要时间坐标。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10